Patrys to initiate clinical trial with Onyx Pharmaceuticals
In November 2013, Patrys announced it would initiate an Investigator-sponsored clinical trial using PAT-SM6 in combination with Onyx Pharmaceuticals' carfilzomib.
Successful PAT-SM6 Phase I/IIa clinical trial in multiple myeloma
In March 2014, Patrys announced the final results from its Phase I/IIa clinical trial in multiple myeloma with anti-cancer drug PAT-SM6 at The University Hospital of Würzburg.
Peer reviewed publications support PAT-SM6 as an anti-cancer treatment
Patrys has recently focussed on submitting manuscripts to peer reviewed scientific publications in an effort to promote its products, technologies and platform which has not previously been done
PAT-SC1 gastric cancer clinical trial 10-year follow up data published
In January 2014, Patrys announced the publication of a new scientific article in Oncology Reports regarding positive results from a follow-up of gastric cancer patients who were treated with anti-cancer compound PAT-SC1.
